GS

Gyan Singh Ghansodiya

Active Director Director/Designated Partner DIN 11776360
DIN 11776360 First appointment Aug 2026
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2026
Shareholding value β€’β€’β€’β€’ Premium profile

About Gyan Singh Ghansodiya

Gyan Singh Ghansodiya is a Director/Designated Partner at Alfamed Pharma Private Limited (since 2026).

DIN 11776360
Primary Designation Director/Designated Partner
First Appointment 17 Aug 2026

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Alfamed Pharma Private Limited U21002DL2026PTC467564
Director/Designated Partner17 Aug 20262026Active

Board colleagues of Gyan Singh Ghansodiya

NameDINCompanyDesignation
Jyoti Rajak11776359Alfamed Pharma Private LimitedDirector
Kripal Singh KaranjaAlfamed Pharma Private LimitedIndividual Subscriber

Directorship timeline

Open interactive timeline →
Alfamed Pharma Private Limited
Premium access

Shareholding and investment profile for Gyan Singh Ghansodiya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gyan Singh Ghansodiya

Gyan Singh Ghansodiya currently holds 1 directorship: Alfamed Pharma Private Limited (Director/Designated Partner, since 17 Aug 2026).

Gyan Singh Ghansodiya was first appointed on 17 Aug 2026 as Director/Designated Partner at Alfamed Pharma Private Limited.

The current boards of Gyan Singh Ghansodiya's companies include Jyoti Rajak (Alfamed Pharma Private Limited), Kripal Singh Karanja (Alfamed Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available